Literature DB >> 15833357

Death receptor-mediated apoptosis in human malignant glioma cells: modulation by the CD40/CD40L system.

Jörg Wischhusen1, Dagmar Schneider, Michel Mittelbronn, Richard Meyermann, Hartmut Engelmann, Gundram Jung, Heinz Wiendl, Michael Weller.   

Abstract

CD40, a TNF-R-related cell surface receptor, is shown here to be expressed by glioma cells in vitro and in vivo. Glioma cell lines expressing low levels of CD40 at the cell surface resist cytotoxic effects of CD40L. CD40 gene transfer sensitizes glioma cells to CD40L. Inhibition of protein synthesis potentiates cell death which involves CD40 clustering and caspases 8 and 3 processing. CD40-transfected LN-18 cells acquire resistance to CD95L. In contrast, subtoxic concentrations of CD40L strongly sensitize these cells for TNF-alpha-induced apoptosis. Bispecific CD40xCD95 antibodies specifically kill glioma cells, disclosing the property of endogenous CD40 to facilitate death signalling.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15833357     DOI: 10.1016/j.jneuroim.2005.01.005

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  15 in total

1.  Local convection-enhanced delivery of an anti-CD40 agonistic monoclonal antibody induces antitumor effects in mouse glioma models.

Authors:  Takuhiro Shoji; Ryuta Saito; Masashi Chonan; Ichiyo Shibahara; Aya Sato; Masayuki Kanamori; Yukihiko Sonoda; Toru Kondo; Naoto Ishii; Teiji Tominaga
Journal:  Neuro Oncol       Date:  2016-02-24       Impact factor: 12.300

2.  CD40/CD40L expression correlates with the survival of patients with glioblastomas and an augmentation in CD40 signaling enhances the efficacy of vaccinations against glioma models.

Authors:  Masashi Chonan; Ryuta Saito; Takuhiro Shoji; Ichiyo Shibahara; Masayuki Kanamori; Yukihiko Sonoda; Mika Watanabe; Toshiaki Kikuchi; Naoto Ishii; Teiji Tominaga
Journal:  Neuro Oncol       Date:  2015-05-24       Impact factor: 12.300

3.  The CD40/CD40L axis in glioma progression and therapy.

Authors:  Paul R Walker; Denis Migliorini
Journal:  Neuro Oncol       Date:  2015-07-22       Impact factor: 12.300

4.  [Gd@C(82)(OH)(22)](n) nanoparticles inhibit the migration and adhesion of glioblastoma cells.

Authors:  Jing Wang; Feng Gu; Ting Ding; Xiaoli Liu; Gengmei Xing; Yuliang Zhao; Ning Zhang; Yongjie Ma
Journal:  Oncol Lett       Date:  2010-07-01       Impact factor: 2.967

5.  TNFα regulates the localization of CD40 in lipid rafts of glioma cells.

Authors:  Richa Tewari; Saurav Roy Choudhury; Veer Singh Mehta; Ellora Sen
Journal:  Mol Biol Rep       Date:  2012-06-15       Impact factor: 2.316

6.  Gastric cancer cell lines AGS before and after CD40 signal activating.

Authors:  Rui Li; Xue-Qin Pang; Wei-Chang Chen; Ling Li; Wen-Yan Tian; Xue-Guang Zhang
Journal:  Mol Biol Rep       Date:  2012-02-21       Impact factor: 2.316

7.  Apoptosis-associated genes related to photodynamic therapy in breast carcinomas.

Authors:  J C Silva; J Ferreira-Strixino; L C Fontana; L M Paula; L Raniero; A A Martin; R A Canevari
Journal:  Lasers Med Sci       Date:  2014-02-27       Impact factor: 3.161

8.  Activation of CD40 by soluble recombinant human CD40 ligand inhibits human glioma cells proliferation via nuclear factor-κB signaling pathway.

Authors:  Yong Zhang; Tao Huang; Yi Hu; Yu Wang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2012-10-18

9.  Combination of an agonistic anti-CD40 monoclonal antibody and the COX-2 inhibitor celecoxib induces anti-glioma effects by promotion of type-1 immunity in myeloid cells and T-cells.

Authors:  Akemi Kosaka; Takayuki Ohkuri; Hideho Okada
Journal:  Cancer Immunol Immunother       Date:  2014-05-31       Impact factor: 6.968

10.  Tumor targeting using magnetic nanoparticle Hsp70 conjugate in a model of C6 glioma.

Authors:  Maxim A Shevtsov; Ludmila Y Yakovleva; Boris P Nikolaev; Yaroslav Y Marchenko; Anatolii V Dobrodumov; Kirill V Onokhin; Yana S Onokhina; Sergey A Selkov; Anastasiia L Mikhrina; Irina V Guzhova; Marina G Martynova; Olga A Bystrova; Alexander M Ischenko; Boris A Margulis
Journal:  Neuro Oncol       Date:  2013-12-04       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.